GlassScriptPhysician profile
Aurea P Thomas
NPI 1255701090
$1,356.77
in general payments reported to CMS, 2019-2025
21 companies · $285 in 2025
The $285 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.60 · 2020: $40.20 · 2021: $236 · 2022: $57.96 · 2023: $236 · 2024: $431 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $202.91 | 2021-2025 | Sublocade |
| Sanofi-Aventis U.S. LLC | $197.46 | 2023-2025 | |
| Esperion Therapeutics, INC. | $133.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $132.19 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $117.97 | 2024 | Lynparza |
| Cranial Technologies, INC | $109.20 | 2020-2025 | Doc Band |
| Glaxosmithkline, LLC. | $95.71 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $53.00 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.80 | 2023-2025 | |
| Mannkind Corporation | $40.44 | 2023 | Afrezza |
| Braeburn INC. | $37.78 | 2023-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $34.75 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $31.62 | 2023-2024 | Inpefa |
| Recordati_rare_diseases_inc. | $22.23 | 2025 | Isturisa |
| Sanofi Pasteur INC. | $20.83 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $18.99 | 2023 | Korlym |
| Teva Pharmaceuticals USA, INC. | $16.21 | 2025 | Uzedy |
| Pear Therapeutics (US), INC. | $12.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.62 | 2019 | |
| Athena Bioscience, LLC | $11.50 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurea Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.